ABSTRACT IMPORTANCE AND OBJECTIVE Partial gland ablation (PGA) is increasingly popular as a treatment for men with intermediate-risk prostate cancer (IR-PCa) to preserve functional outcomes

while controlling their cancer. We aimed to determine the impact of race and clinical characteristics on the risk of upstaging (≥pT2c) and having adverse pathological outcomes including

seminal vesicle invasion (SVI), extra prostatic extension (EPE) and lymph node invasion (LNI) at radical prostatectomy (RP) among men with IR disease eligible for PGA with hemi-ablation

(HA). DESIGN Retrospective analysis. SETTING Multicenter. PARTICIPANTS AND MEASURES We studied patients diagnosed with unilateral IR-PCa treated with RP between 1988 and 2020 at 9 different

men, AA individuals were younger (61 vs. 65 years, _p_ < 0.001), presented with a higher prostate specific antigen (PSA) category (≥10 ng/ml; 34 vs. 26%, p < 0.001), and had a lower

clinical stage (_p_ < 0.001). Among the 2,798 (89.5%) with ≥pT2c stage, AA men exhibited higher ≥ pT2c rates (93 vs. 89%, _p_ < 0.001), primarily due to increased pT2c staging (64 vs.

57%), where upstaging beyond pT2 was lower than non-AA men (29 vs. 32%). On multivariable analysis, AA men were found to have higher odds of ≥pT2c (odds ratio [OR]: 1.39 CI, 1.02–1.88, _p_ =

 0.04), lower odds of EPE (OR: 0.73 CI, 0.58–0.91, _p_ < 0.01) and no statistically significant associations with LNI (OR: 0.79 CI, 0.42–1.46, _p_ = 0.45) and SVI (OR: 1 CI, 0.74–1.35,

_p_ = 0.99) compared to non-AA men. On multivariable analysis, clinical features associated with higher odds of ≥pT2c were pre-operative PSA ≥ 15 (OR = 2.07, _P_ = 0.01) and higher number of

positive cores (HPC) on biopsy (OR = 1.36, _P_ < 0.001). Similarly, PSA ≥ 15, Gleason grade ≥3 and HPC on biopsy were associated with higher odds of SVI, EPE and LNI, respectively.

CONCLUSIONS In men with IR-PCa undergoing RP, AA men demonstrated an overall higher likelihood of ≥pT2c with lower upstaging beyond pT2, lower likelihood of EPE and no significant difference

in likelihood of SVI and LNI compared to non-AA men. These findings support select AA men to be potential candidates for PGA, such as HA. Clinical factors are predictive of higher

pathological stage and adverse pathological outcomes at RP and could be considered when selecting candidates for PGA. Access through your institution Buy or subscribe This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online access $259.00 per year only

$64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS THE ASSOCIATION OF PATIENT

AND DISEASE CHARACTERISTICS WITH THE OVERTREATMENT OF LOW-RISK PROSTATE CANCER FROM 2010 TO 2016 Article 30 March 2024 DOES PRIOR SURGICAL INTERVENTIONAL THERAPY FOR BPH AFFECT THE

ONCOLOGICAL OR FUNCTIONAL OUTCOMES AFTER PRIMARY WHOLE-GLAND PROSTATE CRYOABLATION FOR LOCALIZED PROSTATE CANCER? Article 22 January 2021 CHARACTERISTICS OF INCIDENTAL PROSTATE CANCER IN THE

UNITED STATES Article 23 October 2023 DATA AVAILABILITY The data that support the findings of this study are available on request from the corresponding author. The data are not publicly

available due to privacy or ethical restrictions. REFERENCES * Eastham JA, Boorjian SA, Kirkby E. Clinically localized prostate cancer: AUA/ASTRO guideline. J Urol. 2022;208:505–7. Article 

PubMed  Google Scholar  * Marra G, Ploussard G, Ost P, De Visschere PJL, Briganti A, Gandaglia G, et al. Focal therapy in localised prostate cancer: Real-world urological perspective

explored in a cross-sectional European survey. Urol Oncol. 2018;36:529 e11–e22. Article  PubMed  Google Scholar  * van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry

AM, et al. Focal therapy in primary localised prostate cancer: the European Association of Urology Position in 2018. Eur Urol. 2018;74:84–91. Article  PubMed  Google Scholar  * Polascik TJ,

Tay KJ, Moul JW. Keeping an open mind about novel concepts for management of prostate cancer. Eur Urol. 2015;68:937–8. Article  PubMed  Google Scholar  * Mouraviev V, Mayes JM, Sun L, Madden

JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906–10. Article 

PubMed  Google Scholar  * Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and established technology in focal ablation of the prostate: a systematic review.

Eur Urol. 2017;71:17–34. Article  PubMed  Google Scholar  * Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Fütterer JJ, Rovers MM. An updated systematic review on focal therapy in

localized prostate cancer: what has changed over the past 5 years? Eur Urol. 2022;81:5–33. Article  PubMed  Google Scholar  * Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg

MR, et al. Number of unfavorable intermediate‐risk factors predicts pathologic upstaging and prostate cancer‐specific mortality following radical prostatectomy: results from the SEARCH

database. Prostate. 2017;77:154–63. Article  CAS  PubMed  Google Scholar  * Du XL, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, et al. Racial disparity and socioeconomic status in

association with survival in older men with local/regional stage prostate carcinoma: findings from a large community‐based cohort. Cancer: Interdiscip Int J Am Cancer Soc. 2006;106:1276–85.

Article  Google Scholar  * Mebane C, Gibbs T, Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc. 1990;82:782. CAS  PubMed  PubMed Central  Google

Scholar  * Rebbeck TR, Devesa SS, Chang B-L, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.

Prostate Cancer. 2013;2013:560857. * Virnig BA, Baxter NN, Habermann EB, Feldman RD, Bradley CJ. A matter of race: early-versus late-stage cancer diagnosis. Health Aff. 2009;28:160–8.

Article  Google Scholar  * Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical

characteristics. Eur Urol. 2015;67:451–7. Article  PubMed  Google Scholar  * Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, et al. Unilateral positive biopsies in low

risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU Int.

2012;110:E64–8. Article  PubMed  Google Scholar  * Sfoungaristos S, Perimenis P. Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in

diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates. Can Urol Assoc J. 2013;7:E82–7. Article  PubMed  PubMed Central  Google Scholar  * Tareen B, Godoy G,

Sankin A, Temkin S, Lepor H, Taneja SS. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int. 2009;104:195–9.

Article  PubMed  Google Scholar  * Sinnott M, Falzarano SM, Hernandez AV, Jones JS, Klein EA, Zhou M, et al. Discrepancy in prostate cancer localization between biopsy and prostatectomy

specimens in patients with unilateral positive biopsy: implications for focal therapy. Prostate. 2012;72:1179–86. Article  PubMed  Google Scholar  * Paner GP, Stadler WM, Hansel DE,

Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73:560–9. Article  PubMed  Google Scholar

  * Reddy D, Peters M, Shah TT, van Son M, Tanaka MB, Huber PM, et al. Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic

prostate cancer: a multi-institute 15-year experience. Eur Urol. 2022;81:407–13. Article  PubMed  Google Scholar  * Wysock JS, Becher E, Gogaj R, Velazquez N, Lepor H. Early oncological

control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. Prostate Cancer Prostatic Dis. 2021;24:114–9. Article 

PubMed  Google Scholar  * Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, et al. Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically

significant prostate cancer from a prospective multicentre registry. Eur Urol. 2019;76:98–105. Article  PubMed  Google Scholar  * Delacroix SE, Ward JF. Prostate cancer multifocality: impact

on cancer biology and treatment recommendations. Panminerva Med. 2010;52:209–16. CAS  PubMed  Google Scholar  * Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M.

Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol. 1999;5:139–42. Article  CAS  PubMed  Google Scholar  * Tsodikov A, Gulati R,

de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. 2017;123:2312–9. Article 

PubMed  Google Scholar  * Fuletra JG, Kamenko A, Ramsey F, Eun DD, Reese AC. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in

serum prostate specific antigen. Can J Urol. 2018;25:9193–8. PubMed  Google Scholar  * Kryvenko ON, Balise R, Soodana Prakash N, Epstein JI. African-American men with gleason score 3+3=6

prostate cancer produce less prostate specific antigen than caucasian men: a potential impact on active surveillance. J Urol. 2016;195:301–6. Article  PubMed  Google Scholar  * Nocera L,

Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, et al. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients

treated with radical prostatectomy. World J Urol. 2022;40:103–10. Article  PubMed  Google Scholar  * von Hardenberg J, Borkowetz A, Siegel F, Kornienko K, Westhoff N, Jordan TB, et al.

Potential candidates for focal therapy in prostate cancer in the era of magnetic resonance imaging-targeted biopsy: a large multicenter cohort study. Eur Urol Focus. 2021;7:1002–10. Article

  Google Scholar  * Friedlander DF, Trinh QD, Krasnova A, Lipsitz SR, Sun M, Nguyen PL, et al. Racial disparity in delivering definitive therapy for intermediate/high-risk localized prostate

cancer: the impact of facility features and socioeconomic characteristics. Eur Urol. 2018;73:445–51. Article  PubMed  Google Scholar  * Esdaille AR, Ibilibor C, Holmes A 2nd, Palmer NR,

Murphy AB. Access and representation: a narrative review of the disparities in access to clinical trials and precision oncology in black men with prostate cancer. Urology. 2022;163:90–8.

Article  PubMed  Google Scholar  * Mehralivand S, Shih JH, Harmon S, Smith C, Bloom J, Czarniecki M, et al. A grading system for the assessment of risk of extraprostatic extension of

prostate cancer at multiparametric MRI. Radiology. 2019;290:709–19. Article  PubMed  Google Scholar  * Mazzone E, Stabile A, Pellegrino F, Basile G, Cignoli D, Cirulli GO, et al. Positive

predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol.

2021;4:697–713. Article  PubMed  Google Scholar  * Diamand R, Ploussard G, Roumiguié M, Oderda M, Benamran D, Fiard G, et al. External validation of a multiparametric magnetic resonance

imaging-based nomogram for the prediction of extracapsular extension and seminal vesicle invasion in prostate cancer patients undergoing radical prostatectomy. Eur Urol. 2021;79:180–5.

Article  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS Supported by the United States Department of Veterans Affairs. AUTHOR INFORMATION Author notes * These authors

contributed equally: Sriram Deivasigamani, Eric S. Adams. AUTHORS AND AFFILIATIONS * Department of Urology, Duke University Medical Center, Durham, NC, USA Sriram Deivasigamani, Eric S.

Adams, Srinath Kotamarti, Denis Séguier, Ghalib Jibara & Thomas J. Polascik * Department of Mathematics and Computer Science, College of the Holy Cross, Worcester, MA, USA Shannon Stock

* Department of Urology, Lille University Hospital, Lille, France Denis Séguier * Ziv Medical Center, Safed, Israel Tarek Taha * Division of Urology, Durham VA Medical Center, Durham, NC,

USA Lauren E. Howard, Stephen J. Freedland & Thomas J. Polascik * Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA Alireza Aminsharifi * Oregon

Health and Science University, Portland, OR, USA Christopher L. Amling * Department of Urology, UCLA Medical Center, Los Angeles, CA, USA William J. Aronson * Department of Urology, UCSF

Medical Center, San Francisco, CA, USA Matthew R. Cooperberg * Department of Urology, UC San Diego Health System, San Diego, CA, USA Christopher J. Kane & Lourdes Guerrios-Rivera *

Department of Surgery, Section of Urology, Augusta University- Medical College of Georgia, Augusta, GA, USA Martha K. Terris & Zachary Klaassen * Department of Surgery, University of

Puerto Rico, San Juan, PR, USA Lourdes Guerrios-Rivera * Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA Stephen J. Freedland Authors * Sriram

Deivasigamani View author publications You can also search for this author inPubMed Google Scholar * Eric S. Adams View author publications You can also search for this author inPubMed 

Google Scholar * Shannon Stock View author publications You can also search for this author inPubMed Google Scholar * Srinath Kotamarti View author publications You can also search for this

author inPubMed Google Scholar * Denis Séguier View author publications You can also search for this author inPubMed Google Scholar * Tarek Taha View author publications You can also search

for this author inPubMed Google Scholar * Lauren E. Howard View author publications You can also search for this author inPubMed Google Scholar * Alireza Aminsharifi View author publications

You can also search for this author inPubMed Google Scholar * Ghalib Jibara View author publications You can also search for this author inPubMed Google Scholar * Christopher L. Amling View

author publications You can also search for this author inPubMed Google Scholar * William J. Aronson View author publications You can also search for this author inPubMed Google Scholar *

Matthew R. Cooperberg View author publications You can also search for this author inPubMed Google Scholar * Christopher J. Kane View author publications You can also search for this author

inPubMed Google Scholar * Martha K. Terris View author publications You can also search for this author inPubMed Google Scholar * Zachary Klaassen View author publications You can also

search for this author inPubMed Google Scholar * Lourdes Guerrios-Rivera View author publications You can also search for this author inPubMed Google Scholar * Stephen J. Freedland View

author publications You can also search for this author inPubMed Google Scholar * Thomas J. Polascik View author publications You can also search for this author inPubMed Google Scholar

CONTRIBUTIONS ESA, SD: Methodology, Investigation, Writing-Original Draft. SS: Methodology, Statistical Analysis, writing—Review and Editing. SK, DS: Investigation, Writing-Review &

Editing. TT, LEH, AA, GJ: Methodology, Writing-Review & Editing. CLA, WJA, MRC, CJK, MKT, ZK, LG-R, SJF: Writing-Review & Editing. TJP: Conceptualization, Methodology, Validation and

Supervision. CORRESPONDING AUTHOR Correspondence to Sriram Deivasigamani. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ETHICS APPROVAL The study was

approved by institutional review board with waiver of consent. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps

and institutional affiliations. RIGHTS AND PERMISSIONS Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement

with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and

applicable law. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Deivasigamani, S., Adams, E.S., Stock, S. _et al._ Select black men are potential candidates for prostate

hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer—a multicenter SEARCH cohort study. _Prostate Cancer Prostatic Dis_ (2024).

https://doi.org/10.1038/s41391-024-00880-6 Download citation * Received: 28 April 2024 * Revised: 27 July 2024 * Accepted: 02 August 2024 * Published: 12 August 2024 * DOI:

https://doi.org/10.1038/s41391-024-00880-6 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative